{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-132855","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2024-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.177574+00:00","generated_at":"2026-05-29T09:55:18.787161+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aptevo Therapeutics completes 1-for-37 reverse stock split effective December 3, 2024","bullets":["Certificate of Amendment filed with Delaware; split effective at 5:01 p.m. ET on December 3, 2024.","Every 37 pre-split shares combined into one share; par value unchanged; no fractional shares issued.","Trading on Nasdaq Capital Market begins on split-adjusted basis December 4, 2024; new CUSIP 03835L 405.","Proportionate adjustments made to stock options, RSUs, warrants, and equity plan reserves.","Stockholders' percentage ownership unchanged except for fractional share cash payments."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-132855","json":"https://secwatch.observer/filing/0000950170-24-132855.json","markdown":"https://secwatch.observer/filing/0000950170-24-132855.md","text":"https://secwatch.observer/filing/0000950170-24-132855.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024132855/0000950170-24-132855-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017024132855/apvo-20241203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T09:55:18.787161+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}